Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease

References

• Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest115(4), 957–965 (1999).
   PubMed Web of Science ®Google Scholar
• Ware J, Sherbourne CD. The MOS 36-item short form health survey (SF-36).Conceptual framework and item selection. Med. Care30, 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J.19(2), 217–224 (2002).
   PubMed Web of Science ®Google Scholar
• Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am. J. Respir. Crit. Care Med.155(4), 1283–1289 (1997).
   PubMed Web of Science ®Google Scholar
• Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin. Proc.82(5), 575–582 (2007).
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St George’s Respiratory Questionnaire. Am. Rev. Respir. Dis.145(6), 1321–1327 (1992).
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest127(1), 335–371 (2005).
   PubMed Web of Science ®Google Scholar
• Carone M, Bertolotti G, Anchisi F et al. Analysis of factors that characterize health impairment in patients with chronic respiratory failure. Quality of Life in Chronic Respiratory Failure Group. Eur. Respir. J.13(6), 1293–1300 (1999).
   PubMed Web of Science ®Google Scholar
• Carone M, Jones PW. Health status “quality of life”. In: European Respiratory Monograph: Pulmonary Rehabilitation. Donner CF, Decramer M (Eds). Sheffield, UK, 22–36 (2000).
   Google Scholar
• Carone M, Ambrosino N, Bertolotti G et al. Quality of Life Evaluation and Survival Study: a 3-yr prospective multinational study on patients with chronic respiratory failure. Monaldi Arch. Chest Dis.56(1), 17–22 (2001).
   PubMedGoogle Scholar
• van der Molen T, Willemse BW, Schokker S et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual. Life Outcomes1(1), 13 (2003).
   PubMedGoogle Scholar
• Kocks JW, Tuinenga MG, Uil SM et al. Health status measurement in COPD. The minimal clinically important difference of the Clinical COPD Questionnaire. Respir. Res.7(1), 62 (2006).
   PubMed Web of Science ®Google Scholar
• Antoniu S, Puiu A, Zaharia B, Azoicai D Health-related quality of life and hospitalisations for COPD exacerbations: validity of the Romanian version of the clinical COPD questionnaire. Eur. Respir. J.34(Suppl. 53), 606s (2009).
   Google Scholar
• Jones PW, Harding G, Berry P et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J.34(3), 648–654 (2009).
   PubMed Web of Science ®Google Scholar
• Vincken W. Bronchodilator treatment of stable COPD. Long-acting anticholinergics. Eur. Respir. Rev.14(94), 23–31 (2005).
   Google Scholar
• Scullion JE. The development of anticholinergics in the management of COPD. Int. J. Chron. Obstruct. Pulmon. Dis.2(1), 33–40 (2007).
   PubMedGoogle Scholar
• Wadbo M, Lofdahl CG, Larsson K et al. Effects of formoterol and ipratropium bromide in COPD. A 3-month placebo-controlled study. Eur. Respir. J.20(5), 1138–1146 (2002).
   PubMed Web of Science ®Google Scholar
• Dahl R, Greefhorst LA, Nowak D et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.164(5), 778–784 (2001).
   PubMed Web of Science ®Google Scholar
• Dompeling E, van Schayck CP, Molema J et al. Inhaled beclomethasone improves the course of asthma and COPD. Eur. Respir. J.5(8), 945–952 (1992).
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord JA, Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur. Respir. J.19(2), 209–216 (2002).
   PubMed Web of Science ®Google Scholar
• Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax61(10), 854–862 (2006).
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT), a prespecified subgroup analysis of a randomised controlled trial. Lancet374(9696), 1171–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Kesten S et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur. Respir. J. DOI:10.1183/09031936.00082909 (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med.359(15), 1543–1554 (2008).
   PubMed Web of Science ®Google Scholar
• Appleton S, Jones T, Poole P et al. Ipratropium bromide versus long-acting β2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.3, CD006101 (2006).
   Google Scholar
• Rennard SI, Stoner JA. Challenges and opportunities for combination therapy in chronic obstructive pulmonary disease. Proc. Am. Thorac Soc.2(4), 391–393 (2005).
   PubMedGoogle Scholar
• Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax58(5), 399–404 (2003).
   PubMed Web of Science ®Google Scholar
• Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest112(6), 1514–1521 (1997).
   PubMed Web of Science ®Google Scholar
• Rutten-van Molken M, Roos B, van Noord JA. An empirical comparison of the St George’s Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax54(11), 995–1003 (1999).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Klein GL, Colman SS, Zayed H, Schonfeld WH. Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy. Am. J. Med.120(5), 435–441 (2007).
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ320(7245), 1297–1303 (2000).
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med.340(25), 1948–1953 (1999).
   PubMed Web of Science ®Google Scholar
• Brightling CE, Mckenna S, Hargadon B et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax60(3), 193–198 (2005).
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley PM, Sherwood Burge P, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.163(1), 122–128 (2001).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rennard S, Nelson HS et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir. Res.9, 73 (2008).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J.22(6), 912–919 (2003).
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J.21(1), 74–81 (2003).
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wire P, Horstman D et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.166(8), 1084–1091 (2002).
   PubMed Web of Science ®Google Scholar
• Hanania NA, Darken P, Horstman D et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest124(3), 834–843 (2003).
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet361(9356), 449–456 (2003).
   PubMed Web of Science ®Google Scholar
• Wouters EF, Postma DS, Fokkens B et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax60(6), 480–487 (2005).
   PubMed Web of Science ®Google Scholar
• Celli BR, Macnee W. Standards for the diagnosis and treatment of patients with COPD. A summary of the ATS/ERS position paper. Eur. Respir. J.23(6), 932–946 (2004).
   PubMed Web of Science ®Google Scholar
• Jenkins CR, Jones PW, Calverley PM et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res.10, 59 (2009).
   PubMed Web of Science ®Google Scholar